BirchBioMed is a clinical stage pharmaceutical company focused on developing treatments for scarring (fibrosis) and related skin disorders, certain autoimmune diseases, and for organ fibrosis. We hold the exclusive, worldwide, pharmaceutical licenses from the University of British Columbia (“UBC”) for two scientific technologies, FS1/FS2 and AI-001.